We believe this timeframe will provide sufficient time for hospitals, REHs, and ASCs to assess the impact on quality reporting without disrupting operational and care needs
Understanding its potential causes and knowing how to evaluate and manage elevated B12 levels is key for both clinicians and patients
Even though the benefits will be shorter-lived, you will experience them much sooner
Reported side effects are typically mild and transient: BPC-157: Nausea (rare), mild fatigue in the first week, minor injection site redness TB-500: Mild lethargy during the loading phase, transient head rush immediately after injection, injection site discomfort Combined stack: No documented synergistic toxicity in preclinical or clinical observational data The more significant risks relate to sourcing and administration rather than the peptides themselves
It may even double the death rate for some cancer patients
Patients often report feeling energised sooner